By Fineline Cube Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to calderasib (MK-1084), an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA (pembrolizumab) for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations and expressing PD-L1 (tumor proportion score [TPS] ≥1%). The designation was supported by positive data from the Phase 1 KANDLELIT-001 trial and accelerates Merck’s entry into the rapidly evolving KRAS-targeted therapy market.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Designation | Breakthrough Therapy Designation (BTD) |
| Company | Merck & Co., Inc. (MSD; NYSE: MRK) |
| Drug Combination | Calderasib (MK-1084) + KEYTRUDA (pembrolizumab) |
| Indication | First-line advanced/metastatic NSCLC with KRAS G12C mutation and PD-L1 TPS ≥1% |
| Announcement Date | 29 May 2026 |
| Supporting Data | Phase 1 KANDLELIT-001 trial |
Drug Profile & Development Partnership
- Molecule: Calderasib (MK-1084) – investigational, highly potent and specific next-generation KRAS G12C covalent inhibitor
- Mechanism: Targets the KRAS G12C mutation, present in approximately 13% of NSCLC cases and historically considered “undruggable”
- Combination Rationale: Synergistic approach combining KRAS pathway inhibition with PD-1 immune checkpoint blockade
- Development Consortium: Jointly developed through Merck’s collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals (wholly owned subsidiary of Otsuka Pharmaceutical)
- Oral Administration: Convenient once-daily dosing profile enhancing patient compliance
Clinical and Competitive Landscape
The BTD positions Merck to challenge established players in the KRAS G12C inhibitor space, including Amgen’s Lumakras (sotorasib) and Mirati Therapeutics’ Krazati (adagrasib), both currently approved for second-line NSCLC treatment.
Key competitive advantages of Merck’s approach:
- First-line positioning: Addresses the largest treatment-naïve patient population
- PD-L1 selection: Leverages Merck’s extensive experience with KEYTRUDA biomarker strategies
- Combination synergy: Potential for enhanced efficacy compared to monotherapy approaches
- Integrated development: Seamless transition from KEYTRUDA monotherapy to combination therapy in eligible patients
“The KRAS G12C mutation represents one of the most common oncogenic drivers in lung cancer, yet patients still face limited treatment options,” said Dr. Dean Li, President of Merck Research Laboratories. “This Breakthrough Therapy designation validates our hypothesis that combining calderasib with KEYTRUDA could establish a new standard of care for first-line treatment of this molecularly defined patient population.”
Market Opportunity and Strategic Implications
The first-line KRAS G12C-mutant NSCLC market represents a significant commercial opportunity:
- Addressable Population: Approximately 15,000–20,000 newly diagnosed patients annually in the U.S.
- Revenue Potential: Analysts estimate peak annual sales of $2–3 billion for a successful first-line KRAS combination therapy
- Franchise Extension: Leverages KEYTRUDA’s established commercial infrastructure and physician relationships
- Global Expansion: Similar regulatory pathways available in EU, Japan, and other major markets
Merck plans to advance the combination into Phase 3 development in Q3 2026, with potential approval timelines accelerated by the BTD designation.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory designations, clinical development plans, and market opportunities for calderasib. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech